Double-disk synergy test positivity in Stenotrophomonas maltophilia clinical strains
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
15114869
DOI
10.1007/bf02931649
Knihovny.cz E-resources
- MeSH
- Ampicillin pharmacology MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Drug Resistance, Bacterial MeSH
- beta-Lactams pharmacology MeSH
- beta-Lactamase Inhibitors * MeSH
- Enzyme Inhibitors pharmacology MeSH
- Amoxicillin-Potassium Clavulanate Combination pharmacology MeSH
- Piperacillin, Tazobactam Drug Combination MeSH
- Penicillanic Acid analogs & derivatives pharmacology MeSH
- Microbial Sensitivity Tests methods MeSH
- Piperacillin pharmacology MeSH
- Stenotrophomonas maltophilia growth & development isolation & purification metabolism MeSH
- Sulbactam pharmacology MeSH
- Drug Synergism MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Ampicillin MeSH
- Anti-Bacterial Agents MeSH
- beta-Lactams MeSH
- beta-Lactamase Inhibitors * MeSH
- Enzyme Inhibitors MeSH
- Amoxicillin-Potassium Clavulanate Combination MeSH
- Piperacillin, Tazobactam Drug Combination MeSH
- Penicillanic Acid MeSH
- Piperacillin MeSH
- Sulbactam MeSH
- sultamicillin MeSH Browser
The double-disk synergy test (DDST) using Mueller-Hinton agar and antibiotic disks with centrally positioned disks of amoxicillin-clavulanate, ampicillin-sulbactam, and piperacillin-tazobactam and, at a center-to-center distance of 25-30 mm, 2-4 disks with 10 various beta-lactam antibiotics per one plate was performed in 58 clinical isolates of Stenotrophomonas maltophilia to determine the effectivity of 3 beta-lactamase inhibitors. When tested with clavulanate as the central beta-lactamase inhibitor synergic action on tested strains was the most frequent with aztreonam (81.0% of strains), cefoperazone (63.8%), and cefepime (60.3%). With sulbactam the synergic action, i.e. DDST positivity, was high in the case of cefoperazone (15.5%), ampicillin, aztreonam and piperacillin (8.6% each); with tazobactam it was the most frequent with aztreonam (53.4%), cefoperazone (44.8%) and cefepime (37.9%). No synergy was demonstrated after application of meropenem regardless of the kind of beta-lactamase inhibitor used. In 58 strains of S. maltophilia, 55 different profiles of DDST positivity were found. The results confirm that clavulanate is the most effective inhibitor of S. maltophilia beta-lactamases. The utilization of DDST (performed in the recommended way) for the typization of strains Stenotrophomonas species and for the estimation of potential effectiveness combinations of beta-lactams with beta-lactamase inhibitors for the therapy of stenotrophomonade infections was suggested.
See more in PubMed
Folia Microbiol (Praha). 2002;47(6):742-6 PubMed
Rev Infect Dis. 1988 Jul-Aug;10(4):867-78 PubMed
Antimicrob Agents Chemother. 1994 Sep;38(9):2143-9 PubMed
Antimicrob Agents Chemother. 1994 May;38(5):991-6 PubMed
J Hosp Infect. 1991 Aug;18(4):324-5 PubMed
Infection. 1998 May-Jun;26(3):187-8 PubMed
Antimicrob Agents Chemother. 1982 Oct;22(4):564-70 PubMed
Int J Syst Evol Microbiol. 2000 Jan;50 Pt 1:273-82 PubMed
J Antimicrob Chemother. 1996 Feb;37(2):394-6 PubMed
Antimicrob Agents Chemother. 1995 Jan;39(1):192-9 PubMed
J Antimicrob Chemother. 1998 Apr;41(4):493-4 PubMed
Antimicrob Agents Chemother. 2001 May;45(5):1581-4 PubMed
Antimicrob Agents Chemother. 1994 Oct;38(10):2317-22 PubMed
Diagn Microbiol Infect Dis. 1997 Nov;29(3):129-32 PubMed
Clin Microbiol Rev. 1998 Jan;11(1):57-80 PubMed
Antimicrob Agents Chemother. 1984 Mar;25(3):362-5 PubMed
